- What other names is Androstenetrione known by?
- What is Androstenetrione?
- How does Androstenetrione work?
- Are there safety concerns?
- Dosing considerations for Androstenetrione.
Androstenetrione is promoted as an alternative to "prohormones" such as androstenedione. Marketers claim that androstenetrione increases the body's natural testosterone levels and therefore is free from the negative side effects of prohormones. There is no reliable evidence to back these claims.
Insufficient Evidence to Rate Effectiveness for...
- Improving athletic performance.
- Other conditions.
Quick GuideVitamin D Deficiency: How Much Vitamin D Is Enough?
liver problems, heart problems, and cancer. Avoid using androstenetrione.
Special Precautions & Warnings:It might be UNSAFE for anyone to use androstenetrione, but people with the following conditions have extra reasons to avoid use.
Pregnancy and breast-feeding: Not enough is known about the use of androstenetrione during pregnancy and breast-feeding. Stay on the safe side and avoid use.
Prostate cancer and other hormone-sensitive cancers: Androstenetrione might increase testosterone levels. Men with hormone-sensitive conditions such as prostate cancer should avoid using androstenetrione.
Liver disease: Androstenetrione might increase testosterone levels. Increased testosterone is associated with liver problems. If you have liver disease, don't take androstenetrione. If you have taken androstenetrione, it would be a good idea to have liver function tests (LFTs) done.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Last Editorial Review: 3/29/2011